Letter of intent between Bold Capital Enterprise LTD and Dymedso inc.

PME MTL West-Island is proud to share with you the press release announcing the conclusion of a letter of intent between Bold Capital Enterprise LTD, a Corporation involved in lung disease treatment and treating COVID-19 pulmonary issues, and its client, Dymedso inc.

Over the years, PME MTL West-Island has provided financing to Dymedso inc. and our experts, Jean Archambault and Nathalie Robitaille, have supported the development and commercialization of its flagship product, the Frequencer, which provides airway clearance therapy bronchial drainage by inducing vibration through chest walls.

Today, this announcement not only highlights the start of its funding process, a minimum of $2M and $5M in private placement in Dymedso Inc., but outlines the outstanding potential of the Frequencer in the context of the current pandemic. Although controlled clinical studies on the effectiveness of the Frequencer on COVID-19 patients have not yet been done, more than 650 Frequencers are currently being utilized across the world to assist with airway recruitment and secretion removal. The technology is in use in clinical settings for COVID-19 treatment in Montréal and in Germany.

To learn more about our Commercialization of Innovations team and how we can help you explore new markets and sell your innovative idea, click here.